European regulators have been investigating the safety of Allergan’s Esmya since December, and now they’re advising that no new patients start taking the drug until they wrap up their probe. And meanwhile? The drug is under review for FDA approval.Original Article
No new patients for Allergan’s fibroid drug Esmya, EMA advises amid liver-damage probe
